The Big Picture
The cannabis sector landed in a mixed place heading into the long weekend, with regulatory skirmishes and sharp state-level sales contrasts shaping investor focus. You should note that U.S. markets were closed Saturday, and all price references are as of Friday, Feb 20.
On one side, Canada posted a record retail month in December, signaling steady consumer demand north of the border. On the other side, Michigan opened 2026 with a pronounced sales drop and multiple U.S. policy actions threaten parts of the hemp and adult-use market.
Market Highlights
Here are the quick facts to keep on your radar as you plan for next week.
- Michigan sales plunged in January to $226.8 million, down 8.3% year over year and down 15.9% sequentially, indicating softening demand in a large U.S. market.
- Canada set a new monthly record in December with C$503.7 million in retail cannabis sales, up 5.3% from November on a headline basis.
- Regulatory pressure is rising: Missouri moved forward on a state ban of intoxicating hemp products, Arizona senators approved measures criminalizing ‘‘excessive’’ cannabis smoke or odor, and federal debate continues over a hemp THC ban.
- Licensing and administration items advanced in several states, including Rhode Island weighing how to award up to 20 dispensary licenses and Nebraska moving to update its medical cannabis commission structure.
- Key tickers to watch heading into next week include $MSOS, $TCNNF, $GTBIF, $CURLF, and $TLRY, since these are the primary ETFs and equities investors use to track the sector.
Key Developments
Sales Snapshot: Michigan Slumps, Canada Breaks Records
Michigan reported a weak start to 2026 with January retail sales of $226.8 million, down 8.3% year over year and 15.9% from December. Medical sales collapsed, down 43.4% year over year to roughly $0.4 million for the month, highlighting shifting demand patterns within the state market.
Contrast that with Canada where Statistics Canada reported December retail cannabis sales of C$503.7 million, a new monthly record and a 5.3% increase from November. For your portfolio, that means regional dynamics remain a major driver, and Canadian exposure may offer a different growth profile than U.S. operators right now.
Regulatory Battles: Hemp THC and Local Nuisance Rules
Federal and state policy headlines are mounting. Industry stakeholders urged a two year delay on implementation of a federal hemp THC crackdown, with a GOP congressman and Kentucky officials pressing Senate leadership to pause enforcement. That lobbying effort could be a key near-term win if it delays market disruptions.
At the same time, Missouri’s House passed HB 2641 to ban intoxicating hemp products. Arizona senators approved measures that would make ‘‘excessive’’ cannabis smoke or odor a criminal nuisance punishable by jail time even for legal in-home use. These moves increase legal uncertainty and could compress demand or raise compliance costs in affected states.
Licensing and Administration: Rhode Island and Nebraska Updates
State-level administration remains active. Rhode Island regulators are debating how to award up to 20 retail licenses chosen by lottery, a process applicants want expedited to avoid further sunk costs. That could open a meaningful amount of retail capacity if resolved quickly.
Nebraska’s committee moved to update the Medical Cannabis Commission by adding commissioner pay and fee authority. That kind of administrative build-out may streamline future licensing and regulation, which is a positive sign for orderly market development.
What to Watch
Expect policy and sales data to steer sentiment next week. Which hearings and dates should you mark on your calendar?
- Federal action on the hemp THC delay, including any statements from Senate leadership, will be decisive for hemp-derived product companies. If you hold exposure in that part of the market watch developments closely.
- State legislative calendars in Missouri and Arizona, where bans and nuisance statutes could move to final votes, will matter for operators with local footprints or supply chains tied to those states.
- Retail sales releases: watch for February and regional updates that could confirm whether Michigan’s January drop is an anomaly or the start of a trend. You want to see whether promos or regulatory shifts explain the decline.
- Licensing decisions in Rhode Island set for upcoming lotteries and any timeline updates from regulators. New retail doors can shift local supply dynamics and pricing.
- Keep an eye on sector ETFs and large-cap names including $MSOS, $TCNNF, $GTBIF, $CURLF, and $TLRY for liquidity signals and relative strength heading into Monday trading.
What should you do with this mixed bag of news? Consider being selective with position sizes and ready to adjust if regulatory outcomes swing markets quickly.
Bottom Line
- Regulatory risk remains the dominant near-term factor, with federal hemp THC action and multiple state bills able to reshape local markets.
- Sales divergence is striking. Canada is growing and set a record in December, while Michigan’s January decline warns of U.S. state-level softness you need to monitor.
- Licensing and administrative wins in states like Rhode Island and Nebraska could create pockets of opportunity for new retail entrants.
- Focus on catalysts: federal hemp deliberations, state votes in Missouri and Arizona, and upcoming monthly sales reports.
- Be selective with exposure and size positions so you can react to policy outcomes without overcommitting capital.
FAQ Section
Q: How will a federal hemp THC ban affect companies you own? A: A strict federal ban could disrupt supply chains and sales for firms focused on hemp-derived THC products, pressuring revenues and elevating compliance costs.
Q: Should you buy Canadian cannabis names after December’s record sales? A: Canada’s record month suggests resilient demand, but you should check company fundamentals and valuation before adding exposure, especially if you’re seeking near-term growth.
Q: How quickly will Michigan’s sales decline affect operators? A: The impact varies by company exposure and cost structure, so track upcoming monthly reports and local market pricing to judge whether the drop is temporary or structural.